BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...
The independent journey of CureVac on public markets has concluded. The Nasdaq exchange has suspended trading of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback